Halozyme Therapeutics Company Profile (NASDAQ:HALO)

About Halozyme Therapeutics (NASDAQ:HALO)

Halozyme Therapeutics logoHalozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company's segment also includes research and development activities and product sales of Hylenex recombinant. The Company's development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:HALO
  • CUSIP: 40637H10
  • Web: www.halozyme.com/
  • Market Cap: $2.39 billion
  • Outstanding Shares: 134,013,000
Average Prices:
  • 50 Day Moving Avg: $16.21
  • 200 Day Moving Avg: $13.89
  • 52 Week Range: $8.18 - $18.43
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -22.56
  • P/E Growth: -2.49
Sales & Book Value:
  • Annual Revenue: $134.17 million
  • Price / Sales: 17.80
  • Book Value: $0.43 per share
  • Price / Book: 41.44
  • EBITDA: ($95,850,000.00)
  • Net Margins: -91.15%
  • Return on Assets: -43.18%
  • Debt-to-Equity Ratio: 2.85%
  • Current Ratio: 4.13%
  • Quick Ratio: 3.94%
  • Average Volume: 1.26 million shs.
  • Beta: 2.26
  • Short Ratio: 33.39

Frequently Asked Questions for Halozyme Therapeutics (NASDAQ:HALO)

What is Halozyme Therapeutics' stock symbol?

Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."

How were Halozyme Therapeutics' earnings last quarter?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) posted its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.23) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.25) by $0.02. The firm had revenue of $33.80 million for the quarter, compared to analyst estimates of $31.76 million. The business's quarterly revenue was up 1.2% on a year-over-year basis. During the same period in the previous year, the business posted ($0.21) EPS. View Halozyme Therapeutics' Earnings History.

When will Halozyme Therapeutics make its next earnings announcement?

Halozyme Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for Halozyme Therapeutics.

Where is Halozyme Therapeutics' stock going? Where will Halozyme Therapeutics' stock price be in 2017?

7 analysts have issued twelve-month price objectives for Halozyme Therapeutics' shares. Their forecasts range from $7.00 to $29.00. On average, they anticipate Halozyme Therapeutics' share price to reach $16.71 in the next twelve months. View Analyst Ratings for Halozyme Therapeutics.

Are investors shorting Halozyme Therapeutics?

Halozyme Therapeutics saw a decrease in short interest during the month of September. As of September 29th, there was short interest totalling 13,893,994 shares, a decrease of 31.6% from the September 15th total of 20,302,599 shares. Based on an average trading volume of 1,910,880 shares, the short-interest ratio is currently 7.3 days. Currently, 11.3% of the shares of the stock are sold short.

Who are some of Halozyme Therapeutics' key competitors?

Who are Halozyme Therapeutics' key executives?

Halozyme Therapeutics' management team includes the folowing people:

  • Connie L. Matsui, Chairman of the Board
  • Helen I Torley, President, Chief Executive Officer, Director
  • Laurie D. Stelzer, Chief Financial Officer, Senior Vice President
  • Harry J. Leonhardt Esq., Senior Vice President, Chief Compliance Officer, General Counsel
  • Athena M. Countouriotis M.D., Senior Vice President, Chief Medical Officer
  • Jean-Pierre Bizzari M.D., Independent Director
  • James M. Daly, Independent Director
  • Jeffrey William Henderson, Independent Director
  • Kenneth J. Kelley, Independent Director
  • Randal J. Kirk, Independent Director

Who owns Halozyme Therapeutics stock?

Halozyme Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include KIRK RANDAL J (12.40%) and Fisher Asset Management LLC (0.44%). View Institutional Ownership Trends for Halozyme Therapeutics.

Who sold Halozyme Therapeutics stock? Who is selling Halozyme Therapeutics stock?

Halozyme Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC. View Insider Buying and Selling for Halozyme Therapeutics.

How do I buy Halozyme Therapeutics stock?

Shares of Halozyme Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Halozyme Therapeutics' stock price today?

One share of Halozyme Therapeutics stock can currently be purchased for approximately $17.82.

MarketBeat Community Rating for Halozyme Therapeutics (NASDAQ HALO)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  227 (Vote Outperform)
Underperform Votes:  156 (Vote Underperform)
Total Votes:  383
MarketBeat's community ratings are surveys of what our community members think about Halozyme Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Halozyme Therapeutics (NASDAQ:HALO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 2 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.43)
Consensus Price Target: $16.71 (6.20% downside)
Consensus Price Target History for Halozyme Therapeutics (NASDAQ:HALO)
Price Target History for Halozyme Therapeutics (NASDAQ:HALO)
Analysts' Ratings History for Halozyme Therapeutics (NASDAQ:HALO)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/16/2017Piper Jaffray CompaniesBoost Price TargetOverweight -> Overweight$26.00 -> $29.00N/AView Rating Details
9/15/2017BMO Capital MarketsBoost Price TargetMarket Perform$14.00 -> $15.00MediumView Rating Details
9/15/2017Deutsche Bank AGBoost Price TargetBuy$20.00LowView Rating Details
8/10/2017Jefferies Group LLCReiterated RatingUnderperform$6.75 -> $7.00HighView Rating Details
7/26/2017Canaccord GenuitySet Price TargetBuy$16.00HighView Rating Details
6/23/2017Barclays PLCReiterated RatingOverweight$16.00LowView Rating Details
1/6/2017Citigroup Inc.DowngradeBuy -> NeutralN/AView Rating Details
9/8/2016Wells Fargo & CompanyReiterated RatingBuyN/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$22.00 -> $20.00N/AView Rating Details
(Data available from 10/22/2015 forward)


Earnings History for Halozyme Therapeutics (NASDAQ:HALO)
Earnings by Quarter for Halozyme Therapeutics (NASDAQ:HALO)
Earnings History by Quarter for Halozyme Therapeutics (NASDAQ HALO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017$0.06N/AView Earnings Details
8/8/2017Q2 2017($0.25)($0.23)$31.76 million$33.80 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.25)($0.26)$30.79 million$29.60 millionViewListenView Earnings Details
2/28/2017Q416($0.30)($0.21)$37.94 million$39.00 millionViewListenView Earnings Details
11/7/2016Q316($0.27)($0.23)$34.43 million$31.90 millionViewListenView Earnings Details
8/9/2016Q216($0.27)($0.21)$29.94 million$33.30 millionViewN/AView Earnings Details
5/9/2016Q116($0.20)($0.16)$29.65 million$42.50 millionViewN/AView Earnings Details
2/29/2016Q415($0.08)$0.03$37.06 million$52.20 millionViewListenView Earnings Details
11/9/2015Q315($0.16)($0.19)$24.01 million$20.80 millionViewN/AView Earnings Details
8/10/2015Q215($0.09)$0.02$24.84 million$43.40 millionViewListenView Earnings Details
5/11/2015Q115($0.13)($0.12)$19.40 million$18.70 millionViewListenView Earnings Details
3/2/2015Q414($0.07)($0.04)$25.60 million$30.38 millionViewN/AView Earnings Details
11/10/2014Q314($0.14)($0.16)$16.50 million$14.60 millionViewN/AView Earnings Details
8/11/2014Q214($0.18)($0.13)$13.71 million$18.40 millionViewN/AView Earnings Details
5/12/2014Q114($0.14)($0.22)$13.37 million$12.00 millionViewN/AView Earnings Details
2/27/2014Q413($0.17)($0.19)$21.80 million$12.50 millionViewN/AView Earnings Details
11/8/2013Q313($0.15)($0.17)$14.62 million$16.00 millionViewN/AView Earnings Details
8/7/2013Q2 2013($0.13)($0.13)$11.29 million$14.50 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.15)($0.17)$7.05 million$11.83 millionViewN/AView Earnings Details
2/25/2013Q4 2012($0.16)($0.04)$7.32 million$21.80 millionViewN/AView Earnings Details
11/8/2012Q312($0.13)($0.18)$6.09 million$5.33 millionViewN/AView Earnings Details
8/6/2012($0.15)($0.13)ViewN/AView Earnings Details
5/7/2012($0.11)$0.14ViewN/AView Earnings Details
3/9/2012($0.16)($0.18)ViewN/AView Earnings Details
11/7/2011($0.03)$0.05ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Halozyme Therapeutics (NASDAQ:HALO)
2017 EPS Consensus Estimate: ($1.07)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.27)($0.27)($0.27)
Q2 20171($0.27)($0.27)($0.27)
Q3 20171($0.27)($0.27)($0.27)
Q4 20171($0.26)($0.26)($0.26)
(Data provided by Zacks Investment Research)


Dividend History for Halozyme Therapeutics (NASDAQ:HALO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Halozyme Therapeutics (NASDAQ:HALO)
Insider Ownership Percentage: 16.80%
Institutional Ownership Percentage: 85.06%
Insider Trades by Quarter for Halozyme Therapeutics (NASDAQ:HALO)
Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)
Insider Trades by Quarter for Halozyme Therapeutics (NASDAQ:HALO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/20/2015Laurie StelzerCFOBuy10,000$17.24$172,400.00View SEC Filing  
6/18/2015Kenneth J KelleyDirectorSell20,000$21.00$420,000.00View SEC Filing  
9/16/2014David A RamsayCFOBuy25,000$8.90$222,500.00View SEC Filing  
9/16/2014Helen TorleyCEOBuy50,000$8.92$446,000.00View SEC Filing  
8/19/2014John Stuart PattonDirectorSell75,000$9.96$747,000.00View SEC Filing  
5/15/2014Robert EnglerDirectorSell126,700$7.56$957,852.00View SEC Filing  
9/16/2013John Stuart PattonDirectorSell75,000$9.13$684,750.00View SEC Filing  
8/19/2013H. Michael ShepardVPSell10,000$7.11$71,100.00View SEC Filing  
8/14/2013Kathryn FalbergDirectorBuy100,000$6.82$682,000.00View SEC Filing  
11/29/2012Robert EnglerDirectorBuy15,000$5.57$83,550.00View SEC Filing  
11/14/2012James P ShafferVPBuy20,000$5.22$104,400.00View SEC Filing  
11/13/2012Kathryn E FalbergDirectorBuy50,000$5.21$260,500.00View SEC Filing  
8/27/2012Kenneth J KelleyDirectorBuy20,000$5.70$114,000.00View SEC Filing  
8/13/2012Gregory Ian FrostCEOBuy2,000$5.50$11,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Halozyme Therapeutics (NASDAQ:HALO)
Latest Headlines for Halozyme Therapeutics (NASDAQ:HALO)
Loading headlines, please wait.



Halozyme Therapeutics (HALO) Chart for Sunday, October, 22, 2017

This page was last updated on 10/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.